Short-term efficacy of monthly pamidronate infusion in patients with osteogenesis imperfecta

Journal of Korean Medical Science

Volumn 22, Issue 2, 2007, Pages 209-212

  Choi, Jin Ho ^a   Shin, Young Lim ^b   Yoo, Han Wook ^b  

^a Chungnam National University College of Medicine   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

Author keywords

Osteogenesis imperfecta; Pamidronate

Indexed keywords

EID: 34248564579     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2007.22.2.209     Document Type: Article

References (25)

1. Sykes B, Ogilvie D, Wordsworth P, Wallis G, Mathew C, Beighton P, Nicholls A, Pope FM, Thompson E, Tsipouras P. Consistent linkage of dominantly inherited osteogenesis imperfecta to the type I collagen loci: COL1A1 and COL1A2. Am J Hum Genet 1990; 46: 293-307.
2. Marini JC, Chernoff EJ. Osteogenesis imperfecta. In: Cassidy SB, Allanson JE, eds. Management of genetic syndromes. Philadelphia: Wiley-Liss Inc 2001; 281-300.
3. Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Gene 1979; 16: 101-16.
4. Rauch F, Glorieux FH. Osteogenesis imperfecta. Lancet 2004; 363: 1377-85.
5. Lee YS, Low SL, Lim LA, Loke KY. Cyclic pamidronate infusion improves bone mineralisation and reduces fracture incidence in osteogenesis imperfecta. Eur J Pediatr 2001; 160: 641-4.
6. Astrom E, Soderhall S. Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta. Arch Dis Child 2002; 86: 356-64.
7. Bembi B, Parma A, Bottega M, Ceschel S, Zanatta M, Martini C, Ciana G. Intravenous pamidronate treatment in osteogenesis imperfecta. J Pediatr 1997; 131: 622-5.
8. Falk MJ, Heeger S, Lynch KA, DeCaro KR, Bohach D, Gibson KS, Warman ML. Intravenous bisphosphonate therapy in children with osteogenesis imperfecta. Pediatrics 2003; 111: 573-8.
9. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 1998; 339: 947-52.
10. Plotkin H, Rauch F, Bishop NJ, Montpetit K, Ruck-Gibis J, Travers R, Glorieux FH. Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J Clin Endocrinol Metab 2000; 85: 1846-50.
11. Rauch F, Plotkin H, Travers R, Zeitlin L, Glorieux FH. Osteogenesis imperfecta types I, III, and IV: effect of pamidronate therapy on bone and mineral metabolism. J Clin Endocrinol Metab 2003; 88: 986-92.
12. Rauch F, Travers R, Plotkin H, Glorieux FH. The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. J Clin Invest 2002; 110: 1293-9.
13. Zeitlin L, Rauch F, Plotkin H, Glorieux FH. Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV. Pediatrics 2003; 111: 1030-6.
14. Zacharin M, Bateman J. Pamidronate treatment of osteogenesis imperfecta - lack of correlation between clinical severity, age at onset of treatment, predicted collagen mutation and treatment response. J Pediatr Endocrinol Metab 2002; 15: 163-74.
15. Korean Pediatric Society. References for Korean children's physical development. 1998. Available at http://www.pediatrics.or.kr/default. asp [accessed 16 May 2006].
16. Bleck EE. Nonoperative treatment of osteogenesis imperfecta: orthotic and mobility management. Clin Orthop Relat Res 1981; 159: 111-22.
17. Kim BY, Kim YG, Kim YJ, Yoo KH, Lee JW, Kim SK. A study of bone marrow density in Korean children of normal growth and development. J Korean Pediatr Soc 1995; 38: 612-8.
18. Lee SW, Kim HJ, Cho JH, Lee HS, Jung YM, Kim DJ, Lee KW, Chung YS. Effects of pamidronate treatment on osteogenesis imperfecta. J Korean Soc Endocrinol 2004; 19: 485-91.
19. Cho TJ, Park MS, Choi IH, Chung CY, Yoo WJ. Efficacy of cyclic intravenous pamidronate therapy for children with osteogenesis imperfecta. J Korean Orthop Assoc 2003; 38: 741-7.
20. Srivastava T, Alon US. The role of bisphosphonates in diseases of childhood. Eur J Pediatr 2003; 162: 735-51.
21. Lindsay R. Modeling the benefits of pamidronate in children with osteogenesis imperfecta. J Clin Invest 2002; 110: 1239-41.
22. Srivastava T, Alon US. Bisphosphonates: from grandparents to grandchildren. Clin Pediatr (Phila) 1999; 38: 687-702.
23. Vasikaran SD. Bisphosphonates: an overview with special reference to alendronate. Ann Clin Biochem 2001; 38: 608-23.
24. Vitte C, Fleisch H, Guenther HL. Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption. Endocrinology 1996; 137: 2324-33.
25. Brumsen C, Hamdy NA, Papapoulos SE. Long-term effects of bisphosphonates on the growing skeleton. Studies of young patients with severe osteoporosis. Medicine (Baltimore) 1997; 76: 266-83.